The US Department of Justice has charged Glenmark with conspiring with Apotex Corp, others to increase the price of cholesterol medication pravastatin and other generic drugs
Drugmaker Glenmark has said it will “vigorously defend” its position in a case of alleged price fixing in the United States.
The company’s shares were down over 5 percent on the BSE, at ₹425 (at 11 am) on Wednesday, on news that the US Department of Justice had charged the company with “conspiring” to fix prices on generic drugs.
In a statement to BusinessLine, the company said: “We strongly disagree with the charges ...
Read the full text thehindubusinessline